The exit of metastasizing tumor cells from the vasculature, extravasation, is regulated by their dynamic interactions with the endothelial cells that line the internal surface of vessels. To elucidate signals controlling tumor cell adhesion to the endothelium and subsequent transendothelial migration, we performed phosphoproteomic analysis to map cell-specific changes in protein phosphorylation that were triggered by contact between metastatic MDA-MB-231 breast cancer cells and endothelial cells. . When EPHA2 phosphorylation dynamics were compared between cell lines of different metastatic ability, EPHA2-Tyr 772 was rapidly dephosphorylated after ephrinA1 stimulation specifically in cells targeting the lung. Knockdown of the phosphatase LMW-PTP reduced adhesion and transendothelial migration of the breast cancer cells. Overall, cell-specific phosphoproteomic analysis provides a bidirectional map of contact-initiated signaling between tumor and endothelial cells that can be further investigated to identify mechanisms controlling the transendothelial cell migration of cancer cells.
INTRODUCTION
Metastasis is a multistep process in which tumor cells must first enter and survive in the circulation before exiting the vascular system for colonization of secondary organs (1) . Extravasation requires metastasizing cells to cross the endothelial barrier of blood vessel walls. The initial steps of extravasation are governed by dynamic interactions between tumor and endothelial cells. For example, live-cell image analyses have shown that tumor cells first adhere to and then migrate along the vessel before traversing the endothelium-a highly interactive process that involves morphological changes and cytoskeletal reorganization in both the cancer cells and the endothelial cells (2) (3) (4) . Efforts to dissect tumor cell extravasation have uncovered various regulatory molecules, such as E-selectin and vascular endothelial growth factor receptor (VEGFR) in endothelial cells (5-7) and integrin b 1 (8) (9) (10) and CD82 (11, 12) in tumor cells. Proteins regulating tumor cell and endothelial cell interactions can promote or hinder cancer cell escape from the circulation as demonstrated by targeting lectin-dependent tumorendothelial adhesion, which effectively reduces metastatic burden (13) . However, the dynamic signaling pathways that drive tumor-endothelial interactions remain poorly characterized, which limits the development of therapeutic strategies targeting disseminating cancer cells.
A technical constraint in studying dynamic tumor-endothelial signaling is the requirement for direct cell-cell contact between two different cell populations. System-wide analysis of these heterotypic interactions is a challenge because cocultured cells must be lysed together for biochemical processing, which can result in the loss of the ability to detect the distinct molecular changes occurring in each cell type. Consequently, studies of molecular players that govern the interplay between tumor and endothelial cells have mostly used candidate-based approaches, which are limited by existing knowledge of the events that control extravasation.
Mass spectrometry (MS) provides a sensitive method for detection and quantification of proteins and posttranslational modifications, which enables untargeted, system-wide study of cell signaling. Additionally, stable isotope labeling of cells in culture (SILAC) is a method of introducing isotopomeric versions of amino acids into cellular proteomes, which can be used to facilitate MS analysis of contact-initiated signaling between different cell types in a cell-specific manner (14) (15) (16) .
Here, we used a SILAC-based phosphoproteomic strategy to uncover bidirectional signaling pathways that are regulated upon contact between human breast cancer cells [the LM2 metastatic subpopulation derived from the MDA-MB-231 cell line (17) ] and endothelial cells [human umbilical vein endothelial cells (HUVECs)]. We identified the ephrin type A receptor 2 (EPHA2) as a protein that exhibited contact-induced changes in phosphorylation state and subsequently determined that EPHA2 negatively regulated tumor cell-endothelial cell adhesion and transendothelial migration of breast cancer cells. We observed that phosphorylation of the EPHA2 activation loop Tyr 772 was decreased in LM2 cells upon interaction with endothelial cells. We showed that phosphorylation of EPHA2-Tyr 772 was critical for EPHA2-mediated inhibition of transendothelial migration. Compared with the dynamics of EPHA2-Tyr 772 phosphorylation in the less metastatic parental MDA-MB-231 cell population, phosphorylation of EPHA2-Tyr 772 was rapidly decreased in LM2 cells after stimulation with ephrinA1 ligand. This dynamic regulation of EPHA2-Tyr 772 by ephrinA1 was specifically altered in cancer cells with increased lung metastatic potential compared with those that metastasized to other tissues. Identification of such EPHA2-based regulation of transendothelial migration highlights the value of using cell-specific phosphoproteomics to provide mechanistic insight into the signaling events underpinning complex cell-cell interactions.
RESULTS

SILAC labeling enables cell-specific analysis of contact-initiated signaling between tumor cells and endothelial cells
To elucidate the dynamics of the signaling pathways underlying tumor cell extravasation, we conducted a cell-specific phosphoproteomic analysis of contact-initiated signaling between tumor and endothelial cells. We used an in vivo-selected lung metastatic derivative of MDA-MB-231 cells [subpopulation LM2-4175 (17) , hereafter referred to as LM2] as a cancer cell model system. We confirmed that LM2 cells adhere to and transmigrate through an endothelial cell monolayer more efficiently than the parental population from which they were derived (fig. S1, A and B) (18) , indicating that signaling pathways driving extravasation are enriched within this cell population. By monitoring the kinetics of LM2 cell attachment to a monolayer of HUVECS ( fig. S1B ), we selected to analyze tumor cell-endothelial cell signaling after 15 min of coculture, thereby capturing early signaling events after initial LM2-HUVEC cell contact.
Using SILAC, we introduced cell-specific labels into LM2 cells and HUVECs to ensure that each cell type had a distinct and traceable proteome when tumor and endothelial cells were cocultured and processed for MS analysis. We labeled LM2 cells with the "medium" arginine and lysine isotopomers Arg+6 Da and Lys+4 Da or with the "heavy" isotopomers Arg+10 Da and Lys+8 Da, and we labeled HUVECs with the "light" versions Arg+0 Da and Lys+0 Da. We collected the heavylabeled LM2 cells by enzyme-free cell dissociation buffer (see Materials and Methods), thereby preserving membrane proteins and adhesion receptors, and seeded the cells onto a monolayer of light-labeled HUVECs to simulate early interactions between disseminating tumor cells and the vascular endothelium (Fig. 1A , left panel). After 15 min of coculture, we gently removed any nonadherent LM2 cells and lysed the attached cancer cells together with the HUVECs. In parallel, we collected mediumlabeled LM2 cells that had been maintained as suspension cells in monoculture to represent circulating tumor cells before any contact with the endothelium. These were then added to the harvested LM2-HUVEC coculture in a 1:1 ratio of heavy-labeled/medium-labeled cells to provide a point of reference.
We prepared cytoplasmic-and membrane-enriched fractions, digested the proteins in each fraction, and enriched for phosphopeptides (Fig. 1B) . To normalize changes in phosphopeptide abundance to differences in total protein abundance, we fractionated samples of digested cell lysate in parallel, and we analyzed peptides and phosphopeptides by liquid chromatography-tandem MS (LC-MS/MS). On the basis of SILAC 
LC-MS/MS analysis:
Normalization of phosphopeptide ratios against global ratio of heavy-and medium-labeled proteins Log 2 transformation of Heavy/Medium ratios: log 2 (H/M) C Fig. 1 . Tumor cell-endothelial cell coculture and cell-specific phosphoproteomic analysis. (A) Coculture setup developed to study contact-initiated, phosphorylation-dependent signaling between a highly metastatic LM2 cancer cell population and HUVECS. The cell populations of interest were SILAC-labeled before coculture to enable cell-specific analysis. After coculture of heavy-and light-labeled cells, medium-labeled cells in monoculture were combined as point of reference. Left and right panels depict the two parallel SILAC-labeling strategies used to analyze signaling changes in the LM2 and endothelial cells, respectively. (B) Schematic representation of MS sample preparation. Cell lysates were fractionated and digested, and phosphopeptides were then enriched before LC-MS/MS analysis. (C) Peptides were assigned to cell of origin on the basis of their SILAC label. Changes in the level of identified phosphopeptides were determined from the relative abundance between heavy (coculture) and medium (control) label. Sites were considered to be regulated by an increase or decrease in phosphorylation, where log 2 (heavy/medium) [log 2 (H/M)] ratios were >0.5 or <−0.5, respectively.
labeling of the different cell populations, light-labeled peptides were assigned to HUVECs, medium-labeled peptides to LM2 cells in suspension, and heavy-labeled peptides to LM2 cells that had made contact with HUVECs. Thus, we used the heavy/medium ratio for each phosphopeptide for normalization and quantification of phosphorylation-dependent signaling changes that occurred specifically in the LM2 cells upon contact with HUVECs (Fig. 1C) . Conversely, to elucidate signaling events in HUVECs that were initiated by contacting cancer cells, we seeded light-labeled LM2 cells onto a confluent monolayer of heavy-labeled HUVECs and maintained a monoculture of medium-labeled HUVECs (Fig. 1A, right panel) . After 15 min of coculture, we removed the unattached LM2 cells. We lysed the cocultured cells, mixed them in a 1:1 ratio of heavy-labeled/mediumlabeled HUVECs, and carried out sample preparation and MS analysis as described above. For this setup, light-labeled peptides were assigned to LM2 cells, medium-labeled peptides to HUVECs remaining in monoculture, and heavy-labeled peptides to HUVECs in coculture with tumor cells.
To generate a high-confidence data set, we conducted a minimum of four independent biological experiments for each cell type, which identified a total of 5291 unique phosphopeptides (see fig. S2 for a flow diagram of MS data processing steps). We log 2 -transformed [log 2 (H/M)] the ratio of the extracted ion current of heavy-and medium-labeled phosphopeptides and normalized for gross differences in protein quantity between control and cocultured cells. Subsequently, we combined data for phosphopeptides that represented the same phosphorylation site, which mapped to 2669 unique phosphorylation sites across 1387 unique proteins. From the two separate SILAC coculture experimental setups, we assigned 2279 unique phosphorylation sites to proteins from the LM2 cells and 1080 to proteins from the HUVECs (Fig. 2A) . To focus on proteins that were modulated by either an increase or decrease in phosphorylation after tumor cell-endothelial cell coculture, we filtered identified phosphosites on the basis of a log 2 (H/M) fold change >0.5 or <−0.5 and then manually inspected the raw MS data to eliminate mixed MS/MS spectra, unresolved extracted ion chromatograms, and low SILAC signal intensity. This refined data set provides confident relative quantification of phosphorylation sites for 107 serine, 10 threonine, and 5 tyrosine phosphorylation sites, with 77 and 43 phosphorylation sites modulated in the LM2 cells and HUVECs, respectively [ Fig. 2B and fig. S3 ; see tables S1 and S2 for values of log 2 (H/M) in each biological replicate and overall average fold change].
For phosphorylation sites quantified in a minimum of two independent biological experiments, we performed a two-sided unpaired t test [a = 0.05; −0.5 > log 2 (H/M) > 0.5], which identified a set of core regulated phosphorylation sites in the HUVECs and LM2 cells (Fig. 2B , red bars; see fig. S4 , A and B, for raw values from individual experiments). Global quantification of changes occurring at the protein level highlighted that only 7.9% of the proteins identified in LM2 cells and 9.6% of proteins identified in HUVECs displayed a log 2 (H/M) fold change >0.5 at 15 min of direct coculture ( fig. S5, A and B) . Within these samples, we identified and quantified the protein abundance for 33 of the 92 phosphorylationregulated proteins (Fig. 2B , yellow circles, and tables S3 and S4). Only three phosphoproteins (the myosin phosphatase Rho-interacting protein MPRIP and palladin PALLD in the LM2 cells; the serine/threonineprotein kinase N2 PKN2 in the HUVECs) displayed changes in abundance that closely corresponded with the degree of regulation observed at their specific phosphorylation sites. Overall, these results indicated that most of the identified and quantified changes in site phosphorylation were a consequence of altered kinase or phosphatase activity rather than a change in protein abundance.
Phosphoproteomic analysis of tumor-endothelial contact provides bidirectional map of signaling pathways underlying cancer cell extravasation To provide additional biological context for the changes in phosphorylation status associated with cancer cell attachment to endothelial cells, we mapped the identified phosphorylation-regulated proteins to KEGG pathways (19) and refined the results with manual literature curation. Using this information, we constructed a map of bidirectional signaling and interaction pathways that featured changes in phosphorylation upon tumor cell-endothelial cell contact (Fig. 3) . Many of the identified phosphorylation changes occurred on proteins central to cell-cell adhesion and transendothelial migration. For example, the cell surface receptor CD44, which participates in cell-cell adhesion and tumor cell-endothelial cell interactions (20) , exhibited a decrease in phospho-Ser 706 in the LM2 cells. EPHA2, which mediates homo-and heterotypic cell-cell contact (21), exhibited decreased phosphorylation at two sites in the LM2 cells and an increase in phosphorylation at one site in the HUVECs. Consistent with altered cell adhesion complexes and cytoskeletal rearrangements as important features of cell migration, we detected changes in the phosphorylation status of the integrin b 4 subunit (ITB4) (22) , proteins that regulate the cytoskeleton [such as paxillin (PAXI), talin (TLN1), zyxin (ZYX), and kinectin (KTN1)], and proteins that are components of cellular adhesion complexes [such as nestin (NEST), catenin-b1 (CTNB1), and p120-catenin (CTND1)] (23) (24) (25) (26) .
We also identified changes in phosphorylation status for proteins implicated in the migration of immune cells through the vascular endothelial cells, a process called diapedesis. For example, we identified changes in phosphorylation status of filamin A (FLNA), which is involved in the formation of docking structures surrounding transmigrating neutrophils (27) , in both the endothelial cells and tumor cells. Serine/threonine-protein kinase 10 (STK10) and platelet endothelial cell adhesion molecule (PECA1), which regulate leukocyte transmigration (28) (29) (30) , also showed changes in serine phosphorylation in the LM2 cells. These results suggested that tumor cell and immune cell extravasation may involve similar signaling pathways.
Our analysis not only provides qualitative information about phosphorylation changes but also identifies the specific phosphorylation sites. Agreement between our results and existing knowledge of phosphorylationmediated regulation of cellular adhesion and metastasis validated that our MS approach could successfully identify regulatory signaling behind tumor cell-endothelial cell interactions. For instance, we observed an increase in the phosphorylation of Ser 1166 of the epidermal growth factor receptor (EGFR) in LM2 cells interacting with HUVECs. This site is phosphorylated in cells undergoing integrin-dependent adhesion (31) . We also identified a decrease in phosphorylation of TLN1-Ser 425 in the LM2 cells upon contact with HUVECs. Phosphorylation of this site activates integrin b 1 activity, cell adhesion and motility in vitro, and bone metastasis of prostate cancer cells (32) . Furthermore, we observed decreased phosphorylation of PAXI-Ser 85 , which activates the formation of focal adhesions and membrane protrusions (33) .
We additionally observed the regulation of phosphorylation sites that have not previously been characterized in the context of extravasation. For example, although phosphorylation at Ser 445 , Ser 472 , and Ser 910 regulates the involvement of protein phosphatase 1 regulatory subunit 12A (MYPT1) in cell adhesion (34), we identified Ser 509 as an MYPT1 phosphorylation site that showed a significant decrease in phosphorylation during LM2-HUVEC coculture. This data set thus provides a valuable resource of signaling pathways that may contribute to tumor cell-endothelial cell adhesion and transendothelial migration of metastasizing cancer cells.
EPHA2 is identified as an inhibitor of tumorendothelial adhesion and transendothelial migration
Using the information from the bidirectional signaling map, we selected 20 phosphorylationregulated proteins identified in the LM2 cells to test for a critical role in tumor cell-endothelial cell interactions and tumor cell extravasation. We primarily selected proteins that displayed a pronounced change in their phosphorylation sites (up or down) upon tumor-endothelial contact. We individually knocked down these proteins in LM2 cells using small interfering RNA (siRNA) and measured the effect on cell adhesion to a HUVEC monolayer. Of these, knockdown of EGFR, a known mediator of cell migration (35) , MYPT1, a phosphatase subunit involved in cell adhesion (34), CLIP1 and CLIP2, proteins involved in anchoring organelles to microtubules (36) , and the guidance receptor EPHA2 significantly affected tumor cell-endothelial cell adhesion ( fig. S6A ). This finding suggested that a subset of the LM2 cell proteins that exhibited a change in phosphorylation status in response to HUVEC contact warrant more detailed analysis.
Because EPHA2 knockdown produced the greatest effect with a 1.5-fold increase in tumor cell-endothelial cell adhesion ( fig. S6A ), we validated this effect using two individual siRNA sequences and siRNA of alternative chemistry (Fig. 4, A and  B, and fig. S6 , B and C). The increase in LM2 cell attachment to HUVECs upon EPHA2 knockdown indicated that EPHA2 acts as a negative regulator of tumor cell-endothelial cell adhesion. EPHA2 can either promote cellcell adhesion or repulsion, or regulate cell-substrate attachment (37) . Therefore, we performed adhesion assays on tissue culture plastic to verify that the increase in tumor cell-endothelial adhesion in LM2 cells in which EPHA2 was knocked down was not due to an increase in general cell adhesiveness. EPHA2-knockdown LM2 cells attached to plastic to a similar extent as control LM2 cells ( fig. S6D ), suggesting that EPHA2 specifically inhibited LM2 cell adhesion to HUVECs. Although EPHA2 has been linked to breast cancer metastasis and poor patient prognosis (38-40), a specific role for EPHA2 in the process of extravasation has yet to be explored in breast cancer. To determine whether EPHA2 also regulates LM2 cancer cell migration through the endothelium, we tested the effect of EPHA2 knockdown in a transendothelial migration assay using confluent HUVECs grown on Transwell inserts. EPHA2 knockdown in LM2 cells significantly increased cancer cell transendothelial migration ( Fig. 4C and fig. S6 , B and E), suggesting that EPHA2 inhibits both tumor cell-endothelial cell adhesion and transendothelial migration.
To examine the effect of EPHA2 knockdown on the metastatic behavior of tumor cells in vivo, we injected EPHA2-silenced LM2 cells into the tail vein of nude mice and analyzed the number of tumor cells residing in the lung 20 hours after injection (Fig. 4D) . Consistent with the observations in cultured cells, reduction of EPHA2 significantly increased the retention of LM2 cells in the lungs (Fig. 4E) . Thus, EPHA2 in breast cancer cells may affect the metastasis of these cells by impairing early-stage lung colonization.
EPHA2 inhibits transendothelial migration in several breast cancer cell lines
Having established that EPHA2 is an inhibitor of tumor cell-endothelial cell interactions in LM2 cancer cells, we investigated if EPHA2 performed a similar function in other triple-negative breast cancer cell lines. We selected specific breast cancer cell lines that have been reported to have either high or low endogenous EPHA2 (41) (42) (43) and verified the abundance of EPHA2 by Western blotting. Similar to the MDA-MB-231 cells, SUM149PT cells derived from an inflammatory breast cancer (44) also had abundant EPHA2 (Fig.  4F ), whereas endogenous EPHA2 was low in MDA-MB-468 and MDA-MB-453 cell lines that were isolated from metastatic sites ( Fig. 4F) (45) . Quantitative analysis showed that the amount of EPHA2 in LM2 cells was the same as that in the parental line MDA-MB-231 ( fig. S7A ).
These differences in EPHA2 abundance enabled us to test the effect of knocking down EPHA2 (loss of function) and overexpressing EPHA2 (gain of function) in transendothelial migration assays. As in the LM2 cells, knocking down EPHA2 in the SUM149PT cells significantly increased transendothelial migration ( 
EPHA2-mediated inhibition of transendothelial migration depends on interaction with endothelial ephrinA1
Eph receptor tyrosine kinases interact with their cognate membranetethered ephrin ligands on apposing cells, which elicits a bidirectional response governing the adhesion/repulsion balance (21, 46, 47) . EPHA2 activation by A-type ephrins initiates a cell-cell repulsive response, which suggests a putative mechanism for the EPHA2-mediated inhibition that we observed in transendothelial migration. Hence, ablating the interaction between EPHA2 on tumor cells and its cognate ephrin ligand on endothelial cells should recapitulate the effect of EPHA2 silencing.
We confirmed the presence of ephrinA1 in HUVECs by affinity purification and MS analysis of further showed that LM2 cells bound ephrinA1 and that the ligand-receptor complexes remained at the LM2 cell surface ( fig. S7C ). This indicated that EPHA2 was not internalized in response to binding unclustered, soluble ephrinA1, thus enabling the soluble ligand to function as a competitive ligand for EPHA2. As confirmation, we showed that preincubation of the cells with saturating amounts of soluble, recombinant ephrinA1-Fc reduced LM2 cell adhesion to ephrinA1-coated plates ( fig. S7D ). This indicated that the soluble ligand would be able to block EPHA2-ligand interactions between the two cells. Exposure of LM2 cells to saturating amounts of unclustered ephrinA1-Fc before addition to the confluent HUVEC monolayer for the transendothelial migration assay increased the migration of the cancer cells across the endothelial layer (Fig. 5A ). In the context of the blocking experiment, the increase in transendothelial migration was not due to unclustered ephrinA1-induced reduction in the amount of EphA2 at the cell surface. This indicated that engagement of EPHA2 on the cancer cells by ephrinA1 on the endothelial cells inhibited transendothelial migration of the cancer cells.
Phosphorylation of EPHA2-Tyr 772 is critical for EPHA2-mediated inhibition of transendothelial migration
On the basis of existing models of Eph receptor function (48, 49) , engagement of EPHA2 in LM2 cells by ephrinA1 on HUVECs would initiate EPHA2 phosphorylation, EPHA2 activation, and ephrinA1 cleavage, resulting in cell-cell repulsion. Our phosphoproteomic analysis of contactinitiated signaling showed that, although total EPHA2 abundance remained constant, phosphorylation at EPHA2-Tyr 772 significantly decreased in LM2 cells after interaction with endothelial cells (Figs. 2B and 5B; representative MS2 spectrum identifying the phospho-Tyr 772 EPHA2 peptide shown in Fig. 5C ). This decrease in phosphorylation within the receptor activation loop would reduce Eph receptor activity, favoring a cell-cell adhesive response over a repulsive response (50) (51) (52) . Therefore, we speculated that dephosphorylation of EPHA2-Tyr 772 is a mechanism in these metastatic LM2 cells to subvert EPHA2-mediated inhibition of transendothelial migration (Fig. 6A) .
To investigate the importance of the Tyr 772 phosphorylation site in EPHA2-mediated regulation of transendothelial migration, we stably expressed EPHA2-Y772F or wild-type EPHA2 in the breast cancer cell lines (MDA-MB-468 and MDA-MB-453) with low endogenous amounts of EPHA2 ( fig. S8, A and B, and table S8). The cells expressing this nonphosphorylatable mutant EPHA2 exhibited significantly increased transendothelial migration compared to the cells overexpressing wild-type EPHA2 (Fig. 6B ). This indicated that EPHA2-Tyr 772 phosphorylation in the breast cancer cells was required for EPHA2-dependent inhibition of transendothelial migration.
To determine whether phosphorylation of EPHA2-Tyr 772 is important for EPHA2 kinase activation, we isolated EPHA2-Y772F, wild-type EPHA2, or a kinase-dead mutant, EPHA2-K646M, overexpressed in human embryonic kidney (HEK) 293T cells and performed an in vitro kinase assay with a-enolase as the substrate (Fig. 6C) . Compared to the wild-type receptor, the kinase activity of EPHA2-Y772F was impaired, but compared with the kinase-dead mutant, EPHA2-Y772F retained partial activity (Fig. 6C) . When EPHA2-K646M was stably expressed in MDA-MB-453 cells ( fig. S8, A and B, and table S8), these cells also exhibited increased transendothelial migration compared to cells expressing wild-type EPHA2 (Fig. 6B) . These data suggested that Tyr 772 phosphorylation drives EPHA2-mediated inhibition of transendothelial migration through receptor kinase activation. Because EPHA2-Y772F still demonstrated substantial kinase activity, changes in EPHA2-Tyr 772 phosphorylation do not directly equate to changes in EPHA2 kinase activity, which implies that EPHA2-Tyr 772 phosphorylation may also modulate transendothelial migration through additional, kinase-independent mechanisms.
EPHA2-Tyr
772 phosphorylation dynamics are altered in highly metastatic LM2 cells
Having identified that phosphorylation of EPHA2-Tyr 772 is important for EPHA2-mediated inhibition of transendothelial migration, we explored if altered phosphorylation dynamics of EPHA2-Tyr 772 is a feature of highly metastatic cells. LM2 cells display an enhanced metastatic capacity relative to the parental MDA-MB-231 cells from which they were derived (17, 18) , and we confirmed that the LM2 population showed increased tumor-endothelial adhesion and transendothelial migration in coculture compared to their less aggressive parental counterpart population ( fig.  S1, A and B) . Because we determined that the two cell populations displayed the same amounts of endogenous EPHA2 (Fig. 4F and fig.  S7A ), we investigated if the dynamics of Tyr 772 phosphorylation differed between the two cell populations.
We (Fig. 6D) . fig. S9, A and B) . The decrease in phosphorylated Tyr 772 observed at 10 and 15 min after ephrinA1-Fc stimulation of the LM2 cells was not the result of reduced abundance of EPHA2, because we did not detect a decrease in total EPHA2 abundance until 30 min after stimulation ( fig.  S9C ). Given the importance of EPHA2-Tyr 772 phosphorylation in inhibition of transendothelial migration, the observed decrease of phosphorylated Tyr 772 in the LM2 cells could facilitate tumor cell extravasation and contribute to their increased metastatic potential.
To assess if a similar mechanism contributes to the metastasis of breast cancer cell lines that target different tissues, we examined the Tyr 772 phosphorylation dynamics in two additional MDA-MB-231 metastatic subpopulations: BrM2a, which preferentially metastasizes to the brain (53), and BoM1, which preferentially metastasizes to bone (54) . Time-course analysis of EPHA2 phosphorylation of Tyr 772 across the different MDA-MB-231 populations in response to clustered ephrinA1-Fc showed that, in contrast to the LM2, the BrM2a and BoM1 metastatic cell lines displayed similar EPHA2-Tyr 772 phosphorylation kinetics to the parental MDA-MB-231 population, with a sustained increase in phosphoTyr 772 at 10 and 15 min ( fig. S9D ). These differences among breast cancer cell lines that metastasize to different tissues suggested that the early reduction of EPHA2-Tyr 772 phosphorylation that we identified is only one mechanism for enhanced metastasis of breast cancer cells. Furthermore, these results suggested that there may be EPHA2-specific regulatory events that enable cancer cells to target specific metastatic sites.
The phosphatase LMW-PTP enables cancer cellendothelial cell interactions
One possible mechanism through which EPHA2 tyrosine phosphorylation can be reduced to promote transendothelial migration is through the recruitment of phosphatases (Fig. 6A) . Low-molecular weight protein tyrosine phosphatase (LMW-PTP; encoded by the gene ACP1) negatively regulates the repulsive response of EPHA2 to ephrinA1 stimulation, and EPHA2 desphosphorylation by LMW-PTP is linked to increased oncogenic potential (55) (56) (57) . Additionally, recombinant LMW-PTP can dephosphorylate recombinant EPHA2 at Tyr 772 in vitro (58).
To assess LMW-PTP as a candidate for regulating tumor cell extravasation through EPHA2, we verified that EPHA2 (overexpressed in HEK293T cells) and LMW-PTP (endogenous) coimmunoprecipitated ( fig. S10A ). This highlighted that LMW-PTP can interact with EPHA2. Furthermore, knockdown of LMW-PTP ( fig. S10B ) reduced LM2 cell adhesion to and transmigration through a HUVEC monolayer (Fig. 7, A and  B) . Thus, LMW-PTP is required for effective tumor cell-endothelial cell interactions and may mediate EPHA2-Tyr 772 dephosphorylation to enable tumor cell transendothelial migration.
DISCUSSION
Using cell-specific phosphoproteomic analysis, we present a map of bidirectional phosphorylation-dependent signaling pathways initiated between interacting breast cancer (LM2) and endothelial cells (HUVECs). Through this approach, we identified phosphorylation changes in proteins with known roles in cell-cell adhesion, cytoskeletal remodeling, and leukocyte transmigration, such as EPHA2, CD44, MYPT1, PECA1, and PAXI. Overall, these findings support the notion that signaling pathways relevant to cellular processes within cancer cell extravasation can be identified through the presented workflow.
We observed quantitative changes in key phosphorylation sites upon tumor cell-endothelial cell contact, such as TLN1-Ser 425 and MYPT1-Ser 509 , which provides specific insight into the dynamic modulation of these proteins and indicates their potential involvement in tumor cell extravasation. Similarly, increased phosphorylation of proteins governing membrane trafficking, such as polymerase I and transcript release factor (PTRF), multivesicular body subunit 12A (F125A), and tumor protein D52 (TPD52), revealed additional cellular processes that are regulated upon tumor cell-endothelial cell contact, which could be further investigated.
Moreover, our analysis also provided insights into phosphorylationdependent signaling pathways regulated in the endothelial cells. Consistent with previous in vivo studies showing their active reorganization upon contact with cancer cells (2-4), our phosphoproteomic approach We additionally confirmed that our approach could be used to identify regulators of tumor cell-endothelial cell interaction in cancer cells by demonstrating the functional relevance of several phosphorylation-regulated proteins, such as MYPT1, EGFR, and EPHA2, in tumor cell adhesion to HUVECs. Although we used tumor cellendothelial cell adhesion as a basic phenotype to assess proteins of interest, extravasation of tumor cells involves numerous processes beyond the initial attachment of tumor cells to the endothelium, which are all coordinated through the concerted action of multiple molecular players. Future studies may therefore reveal how phosphoproteins identified in our analysis of tumor cell-endothelial cell signaling contribute to other aspects of tumor cell-endothelial cell interactions, such as transendothelial migration. In support of this, our investigation into EPHA2 highlighted a role for this tumor cell receptor in inhibiting the transendothelial migration and early stages of lung colonization by breast cancer cells. Although it is known (p-Y772) in parental and LM2 MDA-MB-231 cell populations that were stimulated with clustered, soluble ephrinA1-Fc (eA1-Fc). Representative Western blots and quantification of EPHA2 p-Y772 from the indicated number of independent experiments. EPHA2 p-Y772 band intensities were normalized to the respective glyceraldehyde-3-phosphate dehydrogenase (GAPDH) loading controls, and bars show the mean ± SEM of changes in EPHA2 p-Y772 relative to that of nonstimulated cells. All P values were calculated by two-sided ratio paired t test; n.s., not significantly different.
that Eph receptor family members regulate cell-cell contact (21, 46, 47) , our findings present a previously unknown function of EPHA2 in regulating breast cancer interaction with and passage through an endothelial barrier.
A role for EPHA2 in inhibiting transendothelial migration is strikingly paradoxical, given that EPHA2 is reported to have tumor-promoting activities (61-64) and increased EPHA2 expression correlates with increasing metastatic behavior and poor patient prognosis in breast cancer (38) (39) (40) . This discrepancy in EPHA2 function could possibly be rationalized by reported correlations between tumor aggressiveness and a decreased phosphotyrosine content of EPHA2 (61, 62, 65, 66) , which suggest a potential deregulation of the receptor as cancer progresses. Indeed, when comparing MDA-MB-231 populations of different metastatic capacity, we showed that rapid dephosphorylation of the EPHA2-Tyr 772 phosphorylation site occurred selectively in the more highly metastatic LM2 cancer cell population. Our phosphoproteomic analysis of tumor-endothelial signaling identified a significant decrease in EPHA2 Tyr 772 phosphorylation upon LM2 cancer cell contact with endothelial cells, and we further demonstrated that ablating phosphorylation at Tyr 772 compromised EPHA2-mediated inhibition of transendothelial migration.
Although Tyr 772 is the key activation loop tyrosine residue in EPHA2, mutation to prevent phosphorylation at position 772 only partially impaired kinase activity of the receptor. Moreover, in the highly metastatic LM2 cancer cells, phosphorylation-dependent regulation of the activation loop Tyr 772 appeared to be uncoupled from phosphorylation of Tyr 588 ( fig. S9A ), a key juxtamembrane phosphorylation site in EPHA2 receptor activation. We further observed that in addition to the rapid dephosphorylation of Tyr 772 in the LM2 cells after ephrinA1 stimulation, significant down-regulation of the EPHA2 receptor also occurred more rapidly in the LM2 cells compared to the parental cells after prolonged stimulation ( fig. S9C ). These observations are unexpected, given that in existing models of EPH receptor signaling, Tyr 772 phosphorylation is tightly associated with juxtamembrane phosphorylation, receptor kinase activation and subsequent degradation (50) (51) (52) . Our data altogether suggest that EPHA2-Tyr 772 phosphorylation may have additional regulatory roles that are independent from EPHA2 kinase activity.
On the basis of our characterization of EPHA2-Tyr
772
, we propose that targeted Tyr 772 dephosphorylation exists as a molecular switch by which aggressive cancer cells can overcome ligand-driven EPHA2 inhibition of transendothelial migration to facilitate their metastasis. This dynamic reduction in phospho-Tyr 772 is likely to result from phosphatase activity, and we provided evidence that LMW-PTP may be a tyrosine phosphatase that modulates the switch in EPHA2 function to promote tumor cell-endothelial cell interactions.
A similar molecular mechanism based on Akt phosphorylation of EPHA2-Ser 897 has been implicated in regulating the switch between EPHA2-mediated inhibition and promotion of cancer cell migration (67) . Phosphorylation of EPHA2-Ser 897 and ligand-independent EPHA2 signaling have also been associated with increased prostate cancer cell adhesion to and transmigration through bone marrow endothelial monolayers (68) . These examples of site-specific regulation emphasize the importance of considering individual regulatory sites in specific cellular contexts. In contrast to general correlations that have been made between gross phosphotyrosine content of EPHA2 and cancer cell behavior, our findings provide insight into specific regulatory mechanisms underlying the dichotomous pro-and anti-oncogenic functions of EPHA2.
Notably, comparison of EPHA2 phospho-Tyr 772 kinetics between the highly metastatic MDA-MB-231 subpopulations suggested that Tyr 772 dephosphorylation specifically occurred in the lung-selective LM2 cells. These differences in Tyr 772 phosphorylation-dependent regulation underscore the importance of cellular context in studying receptor signaling. Indeed, we observe disparities in the regulation of EPHA2 phosphorylation in LM2 cells between our coculture model system and in ephrinA1-stimulated cells. This may, in part, be due to differences in signal intensity, which we have previously reported for ephrinBdependent activation of EphB2 (16) . Moreover, signaling initiated by cell-cell contact elicits a response that is coordinated through multiple receptors and soluble factors providing several input cues. Ultimately, this highlights the elegance of the SILAC-based phosphoproteomic approach because we can effectively model these multivariate biological systems in a coculture setting, thus enabling the study of complex cell-cell interactions.
Overall, we provide a valuable resource of signaling pathways and specific phosphorylation-dependent signaling events that are initiated upon tumor cell-endothelial cell contact, which reveals previously unknown regulators of tumor-endothelial interaction and highlights the importance of identifying dynamic signaling events in both a cell-and phosphorylation site-specific manner to understand complex cellular behavior.
MATERIALS AND METHODS
Reagents
Tissue culture media were provided by Life Technologies together with the following reagents: OLIGO R3 (1-1339-03), insulin (12585014), zeocin (R25001), Lipofectamine RNAiMAX Transfection Reagent (13778-150), Lipofectamine 2000 (11668027), enzyme-free cell dissociation buffer (13151-014), dialyzed fetal bovine serum (FBS) (26400), CellTracker Green CMFDA (5-chloromethylfluorescein diacetate) (C7025), CellTracker Orange CMRA (C34551), and 4′,6-diamidino-2-phenylindole (DAPI) (D1306). Unless otherwise specified, all other chemicals were purchased from Sigma-Aldrich. , and antibiotic/antimycotic solution. They were grown on tissue culture dishes coated with 0.1% gelatin (G1890) and kept in culture for a maximum of seven passages. All cells were grown in a humidified incubator at 37°C, 5% CO 2 . Cells from noncommercial sources were authenticated by short tandem repeat (STR) profiling. All cell line stocks were routinely tested to confirm the absence of mycoplasma with e-Myco Mycoplasma PCR Detection Kit (iNtRON 25235).
Cell lines
SILAC labeling
Basal SILAC medium (pH 7. (616192) were used for medium labeling; and L-arginine (A8094) and L-lysine (L5501) were used for light labeling. LM2 cells were grown for a minimum of six passages in DMEM-based SILAC labeling medium before use in coculture experiments. For SILAC labeling of HUVECs, RPMI-based SILAC medium was conditioned for 16 hours with fully labeled immortalized human endothelial cells EA.hy926. Conditioned medium was sterile-filtered, diluted 1:1 with fresh RPMI SILAC medium, and supplemented with heparin and endothelial cell growth supplement. HUVECs were grown for two passages in conditioned SILAC medium before use in coculture experiments. The labeling efficiency of LM2 cells and HUVECs was assessed for a minimum of three independent cell cultures for each label.
SILAC coculture for analysis of contact-initiated signaling
HUVECs were grown to confluent monolayers in 15-cm dishes. Before coculture, confluent monolayers of HUVECs were serum-starved for 1.5 hours, and a reserved dish of HUVECs was used for counting. To study the LM2 cell phosphoproteome, fully labeled LM2 cells (~70% confluency) were serum-starved for 16 hours, harvested with enzyme-free cell dissociation buffer, and washed twice in serum-free, basal SILAC DMEM before counting. Heavy-labeled LM2 cells (Arg+10/Lys+8) were plated onto light-labeled HUVECs in a 2:1 LM2/HUVEC cell ratio in a volume of 3 ml per dish. Medium-labeled LM2 cells (Arg+6/Lys+4) were collected and kept in suspension in parallel to the coculture. Cells were incubated for 15 min at 37°C, 5% CO 2 . After incubation, unattached cells were removed from the dishes and counted to estimate the number of LM2 cells remaining attached to HUVEC monolayers. Heavy-labeled LM2 cells and HUVECs were lysed with medium-labeled LM2 cells in a 1:1 heavy/medium cell ratio with ice-cold 0.1 M Na 2 CO 3 (pH 11) supplemented with protease inhibitor cocktail (P8340), phosphatase inhibitor cocktail 3 (P0044), and 10 mM sodium orthovanadate (S6508). To investigate the endothelial cell phosphoproteome, the same protocol for coculture and cell lysis was followed using heavy-and medium-labeled HUVECs with light-labeled LM2 in a 2:1 LM2/HUVEC cell ratio.
Sample preparation and phosphoproteomic analysis
Membrane fractionation and sample preparation were adapted from (70) . Samples were snap-frozen in liquid nitrogen. MgCl 2 was added to 1 mM final concentration for DNA digestion with Benzonase (Novagen, 70746) for 15 min on ice. Cell lysates were then centrifuged at 100,000g for 30 min at 4°C to separate soluble proteins from membrane-associated proteins (pellet). Pellets were washed twice by two rounds of resuspension in lysis buffer followed by 30-min centrifugation before resuspension in 6 M urea, 2 M thiourea, 40 mM ammonium bicarbonate (ABC). Protein concentrations of both cytoplasmic and membrane-enriched fractions were assessed by Bradford protein assay (Bio-Rad). Reduction, alkylation, and digestion were performed by Filter Aided Sample Preparation (FASP; Vivacon 10 K) (71) with 1 mg of total protein per unit. After buffer exchange to 40 mM ABC, proteins were reduced in 20 mM dithiothreitol, 40 mM ABC for 45 min and subsequently alkylated in 50 mM iodoacetamide for 50 min in the dark at room temperature. Then, CaCl 2 was added to a final concentration of 1 mM, and samples were incubated with sialidase A/NANase III (Europa Bioproducts, PZGK80040) and PNGase F (New England Biolabs, P0704) overnight at 37°C to remove sialylation and N-glycosylation. Digestion was performed with Lys-C (Wako, 125-05061) [1% (w/w) enzyme/substrate] for 3 hours at 37°C, followed by addition of trypsin (Worthington) [1% (w/w) enzyme/substrate] for overnight digestion. Digested peptides were recovered by collecting the flow-through and subsequent washes of the FASP column membrane in ABC and then 0.1% trifluoroacetic acid (TFA) in 50% acetonitrile (MeCN). Recovered peptides were dried under vacuum in a Savant SC250 Express SpeedVac concentrator (Thermo Scientific).
All phosphopeptide enrichments were conducted as described in (72) . Dried peptide pellets were resuspended in TiO 2 loading buffer (80% MeCN, 5% TFA, 1 M glycolic acid), and 3 mg of Titansphere TiO 2 beads (10 mm; GL Sciences 5020 75010) was added per 500 mg of peptides for 15-min shaking incubation at room temperature. Beads were then sequentially washed with (i) loading buffer; (ii) 80% MeCN, 1% TFA; and (iii) 10% MeCN, 0.2% TFA. Phosphopeptides were eluted by two incubations with 1% ammonium hydroxide (pH 11.3). The flow-through was then subjected to two more TiO 2 enrichment steps, and the three elutions were pooled. Samples were acidified with a mix of TFA/formic acid (FA), desalted with OLIGO R3 micro-columns packed in-house, and dried under vacuum. For intra-experiment normalization based on global protein H/M ratios, samples of digested cell lysate before phospho-enrichment were fractionated and analyzed in parallel.
Discovery LC-MS/MS of phosphopeptide-enriched samples
Samples were resuspended in 0.1% FA and run on an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific) coupled to a cHiPLC-Nanoflex chromatography system (Eksigent). Reversed-phase chromatographic separation was carried out on a 200-mm inner diameter (i.d.) × 0.5-mm trap column packed with C18 (3-mm bead size, 120 Å, Eksigent) and a 75-mm i.d. × 15-cm column packed with C18 (3-mm bead size, 120 Å, Eksigent) with a linear gradient of 5 to 50% solvent B (100% MeCN + 0.1% FA) against solvent A (100% H 2 O + 0.1% FA) with a flow rate of 300 nl/min. The mass spectrometer was operated in data-dependent mode. Survey scans were performed in the Orbitrap with a resolution of 60,000 at m/z 400 and a Fourier transform target value of 10 6 ions. The 10 most abundant ions were selected for fragmentation by higher-energy collisional dissociation (HCD) and scanned in the Orbitrap at a resolution of 7500 at m/z 400. Selected ions were dynamically excluded for 8 s. For accurate mass measurement, the lock mass option was enabled using the polydimethylcyclosiloxane ion (m/z 455.120025) as an internal calibrant. For peptide identification, raw data files produced in Xcalibur software (Thermo Scientific) were processed in Proteome Discoverer V1.3 (Thermo Scientific) and searched using Mascot (v2.2). Searches were performed with a precursor mass tolerance of 20 parts per million (ppm), a fragment mass tolerance of 0.05 Da, and a maximum of two missed cleavages. Static modifications were limited to carbamidomethylation of cysteine, and variable modifications used were SILAC labels (Lys+4.025 Da; Lys+8.050 Da; Arg+6.020 Da; Arg+10.008 Da); oxidation of methionine; deamidation of asparagine and glutamine; and phosphorylation of serine, threonine, and tyrosine residues. The database used for searching was SwissProt (April 2013; number of entries, 89,601). Peptides were further filtered using a Mascot significance threshold <0.05 and a false discovery rate <0.01 (q value from Percolator 1).
Quantitative analysis of phosphorylation site regulation
For relative phosphopeptide quantification, heavy/medium ratios were determined by Proteome Discoverer (1.3). All further data analysis was performed using the statistical package R (R Development Core Team, 2012; www.R-project.org/). Log 2 (H/M) ratios were compiled for each quantified phosphopeptide and normalized to the median of the log 2 (H/M) value of the input samples, not subjected to phospho-enrichment. Peptide phosphopositions were filtered on the basis of a phosphoRS site probability >60%, where only the best scoring peptide was kept before mapping the position on the protein sequence. UniProt entry names are used in the text and figures to refer to identified proteins. Corresponding UniProt accessions are listed in tables S1 to S4, and more information can be found on www. uniprot.org. One of the identified regulated phosphopeptides could not be uniquely attributed to either CAP-Gly domain-containing linker protein 1 (CLIP1) or 2 (CLIP2) due to sequence similarity and has thus been referred to as "CLIP1/2-S348" (with Ser 348 in CLIP1 corresponding to Ser 352 in CLIP2). Phosphopeptides containing multiple phosphorylated residues have been referenced with all sites featuring phosphorylation (that is, AHNK-S210-S212-S216, which is phosphorylated on Ser ). Spectra were manually assessed to remove mixed spectra, unresolved extracted ion chromatograms, and low SILAC signal intensity to avoid erroneous quantification before further analysis. Phosphorylation sites were then considered regulated if their average log 2 (H/M) was > 0.5 or <−0.5. For each regulated phosphorylation site quantified in a minimum of two independent experiments, an unpaired two-sided t test was performed (a = 0.05). Significant results based on these criteria are referred to as the core set of regulated phosphorylation sites.
Fractionation and LC-MS for quantitative analysis of the cellular proteome
Peptide samples were prepared as described above without the deglycosylation step. High-pH reversed-phase chromatographic separation was performed on an Agilent Zorbax 300Å Extend-C18 column (4.6 × 150 mm, 3.5 mm) using a 21-min stepped linear gradient of 0.5 to 40% solvent B (acetonitrile) against solvent A (H 2 O; 0.1% NH 2 O) and 40 to 85% solvent B against solvent A with a flow rate of 0.4 ml/min. Individual 10-s fractions were collected from 3 to 34 min. The 186 resulting fractions were pooled with equidistance across the gradient (checkboard) into 19 final fractions for LC-MS analysis.
Samples were run on a Q-Exactive Plus mass spectrometer (Thermo Scientific) coupled to a Dionex Ultimate 3000 RSLC nano system (Thermo Scientific). Reversed-phase chromatographic separation was performed on a C18 PepMap 300 Å trap cartridge (0.3-mm i.d. × 5 mm, 5-mm bead size; loaded in a bidirectional manner), a 75-mm i.d. × 50-cm column (5-mm bead size) using a 120-min linear gradient of 0 to 50% solvent B (acetonitrile; 0.1% FA) against solvent A (H 2 O; 0.1% FA) with a flow rate of 300 nl/min. The mass spectrometer was operated in data-dependent mode to automatically switch between Orbitrap MS and MS/MS acquisition. Survey full-scan MS spectra (from m/z 400 to 2000) were acquired in the Orbitrap with a resolution of 70,000 at m/z 400 and FT target value of 1 × 10 6 ions. The 10 most abundant ions were selected for fragmentation using HCD and dynamically excluded for 30 s. Fragmented ions were scanned in the Orbitrap at a resolution of 17,500 at m/z 400. For peptide identification, raw data files were produced in Xcalibur 2.1 (Thermo Scientific) and processed in Proteome Discoverer V1.4 (Thermo Scientific). Searches against the SwissProt human database using Mascot (v2.2) were performed with settings and filters as described above, including only peptide ion scores >20 and unique, proteotypic peptides. For relative protein quantification, the threshold intensity for calculating SILAC ratio was set to the 5% quantile for each sample. For proteins quantified in three or more independent experiments, the relative log 2 (H/M) ratios of their three most intense peptides were averaged to obtain the protein relative quantity between the heavy and medium channels for each experiment.
siRNA knockdown
Primary RNA interference (RNAi) experiments were performed using siGENOME SMARTpool siRNA (Thermo Scientific). Secondary validation of silencing phenotypes was conducted with individual siRNA oligonucleotides of siGENOME or ON-TARGETplus design (Thermo Scientific) or pooled siRNA from FlexiTube GeneSolution (Qiagen). Details of individual siRNA sequences and nontargeting/negative control siRNA used for normalization and statistical comparisons are provided in tables S6 and S7. Transfections were carried out with Lipofectamine RNAiMAX according to the manufacturer's instructions. Cells were transfected with siRNA at a final concentration of 10 nM (siGENOME), 15 nM (Qiagen), or 25 nM (ON-TARGETplus) 72 hours before assaying the impact of silencing.
Tumor cell-endothelial cell adhesion assay
Cancer cells were detached with enzyme-free cell dissociation buffer, washed, and resuspended in Medium 199, 20% FBS before 1 × 10 5 cancer cells were plated onto HUVEC monolayers that had been grown to confluency in a 96-well plate. Cells were cocultured at 37°C, 5% CO 2 for 30 min (unless otherwise specified) , and then the wells were washed to remove unattached cells. The remaining adherent cancer cells were quantified by the Bright-Glo Luciferase Assay System (Promega). Luminescence was measured on a SpectraMax M5 microplate reader, and mean signal intensity was calculated from four replicate wells for each condition. Luminescence of adhering cells was normalized to luminescence from control wells containing the starting number of cancer cells that were plated in parallel.
Transendothelial migration assay
Cancer cells were detached with enzyme-free cell dissociation buffer, washed, and resuspended in Medium 199 GlutaMAX, 2.5% FBS at 5 × 10 5 cells/ml. Tumor cells (5 × 10 4 ) were seeded onto HUVEC monolayers, grown to confluency in the upper chambers of 6.5-mm Transwell inserts with 8.0-mm pore polycarbonate membrane (Corning). The lower chambers were filled with 600 ml of Medium 199, 20% FBS to establish an FBS gradient. Cells were incubated at 37°C, 5% CO 2 for 8 hours before Transwells were emptied and washed with phosphate-buffered saline (PBS). Cells on the lower surface of the Transwell membrane were detached with trypsin and collected by centrifugation. FBS was added to neutralize trypsin, and collected cancer cells were quantified by luciferase assay and measured on a VICTOR X5 multilabel plate reader (PerkinElmer). Mean signal intensity was calculated from four technical replicates of each condition and normalized to luminescence from control wells containing the starting number of cancer cells that were plated in parallel.
In vivo lung retention assay
All animal work was conducted in accordance with UK Home Office guidelines, as established in the Animals (Scientific Procedures) Act 1986, under project license PPL70/7413. No adverse events were observed during the experiments. Cancer cells for in vivo assay were prestained for 45 min with CellTracker dyes made up in serum-free medium to a final concentration of 8 mM. "Experimental" cells, transfected with siRNA (EPHA2 or nontargeting control), were stained with CellTracker Green CMFDA dye. In parallel, nontransfected cells were stained with CellTracker Orange CMRA to serve as an "injection control." Stained cells were allowed to recover in normal growth medium for 6 hours before harvesting using enzyme-free cell dissociation buffer. Experimental (green) cells were mixed in a 1:1 ratio with injection control (orange) cells. Cell mixes were analyzed on a BD LSRII flow cytometer to verify starting green/orange cell ratios for subsequent normalization of acquired data. Twelve female CD-1 nude mice (Charles River), aged between 6 and 8 weeks, were injected in the tail vein with 8 × 10 5 cells in a volume of 100 ml of PBS (six animals per group). After 20 hours, the mice were sacrificed by CO 2 asphyxiation, and whole lungs were excised. Lungs were fixed in 4% formaldehyde/PBS and imaged on a Zeiss 710 confocal microscope under a 20× objective with pinhole diameter set to 1 airy unit. Images were taken at a 512 × 512 resolution as 3 × 3 tiles (1024 mm 2 ), randomly selected on both sides of each lung to give a total of 10 fields of view per lung. Fluorescent cell area quantification was performed using Volocity Image Analysis Software (PerkinElmer).
Identifying ephrins present in HUVECs
To identify ligands of EPHA2 from the HUVEC lysate, HUVECs were grown to confluent monolayers and lysed in a Triton X-100 lysis buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 10 mM NaPPi, 10% glycerol, and 1% Triton X-100; supplemented with sodium orthovanadate and protease and phosphatase inhibitor cocktails]. Affinity pull-downs were performed with a recombinant EphA2-Fc chimera (R&D Systems 639-A2-200), using 1 to 2 mg of bait per 500 mg of protein lysate. Samples were rotated overnight at 4°C before complexes were captured on protein A-Sepharose 4B (P9424). Parallel pull-downs were performed using an Fc fragment to control for identification of nonspecific interactants. To ensure biological reproducibility, pull-downs were performed with four independently cultured samples of HUVECs. Proteins isolated on Sepharose beads were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) for in-gel digestion as previously described (73) . Digestions were carried out with either 100 ng of sequence-grade trypsin (Promega) or 250 ng of AspN (P3303) overnight at 37°C. Extracted peptides were pooled and dried for discovery LC-MS/MS analysis, as described above.
Blocking native EPHA2-ephrinA1 interactions
Cancer cells were harvested by enzyme-free cell dissociation buffer and incubated for 45 min on ice with nonclustered, recombinant ephrinA1-Fc chimera (R&D Systems) at a concentration of 3 mg per 10 6 cells. As a negative control, cells were separately treated in parallel with IgG Fc (Bethyl Laboratories). Cells were washed to remove excess ligand/ antibody before use in in vitro cellular assays. For verifying surface localization of ephrinA1-EPHA2 complexes, cells were fixed with 4% formaldehyde for 15 min before washing and staining with Goat IgG DyLight 650 conjugate antibody (Thermo Scientific SA510121; 2.5 ml per 10 6 cells) for 30 min at room temperature. Flow cytometric analysis was conducted on a BD LSR II flow cytometer and FlowJo vX 10.0.7 (Tree Star Inc.) software.
To test blockade of EPHA2 ligand-binding sites, soluble ephrinA1-Fc was diluted in PBS, and 50 ml was added to the wells of a 96-well plate to provide a coating of 2 mg/cm 2 per well. The plate was coated at 37°C for 2 hours before the wells were washed with cold PBS and blocked with a PBS/1% bovine serum albumin solution for 1 hour at 37°C. Wells were washed with medium before adhesion assay.
Cloning
For generation of luciferase-expressing cancer cell lines, a bicistronic expression construct encoding luciferase and enhanced green fluorescent protein (EGFP) was created by excising and subcloning the luciferase reporter gene from pCLucf (Addgene, 37328) into pcDNA3.1(+) zeo-IRES-EGFP (a gift from B. Howard, ICR) using Eco RI and Bam HI restriction sites. Human EPHA2-Y772F in vector pTargeT (a gift from A. Bennett, Yale University) was polymerase chain reaction (PCR)-amplified with a forward primer containing a Hind III restriction site (5′-TGACAAAGCTTATGGAGCTC-CAGGCAGC-3′) and a reverse primer containing a Xho I site (5′-ATCT-GAACTCGAGTCAGATGGGGATCCCCAC-3′) for subcloning into vector pcDNA3 at the Hind III-Xho I sites. Site-directed mutagenesis was performed to generate an EPHA2-K646M mutant expression construct using a QuikChange II Site-Directed Mutagenesis Kit according to the manufacturer's instructions. Human wild-type EPHA2 in vector pcDNA3 (a gift from T. Pawson) was used as a template for PCR with mutagenesis primers 5′-GTGCCGGTGGCCATCATGACGCTGAAAGCC-3′ and 5′-GGCTTTCAGCGTCATGATGGCCACCGGCAC-3′. The pcDNA3-EPHA2-Y772F and pcDNA3-EPHA2-K646M constructs were verified by DNA sequencing.
Transfections and generations of stable cell lines
All transfections with complementary DNA (cDNA) were carried out using Lipofectamine 2000 according to the manufacturer's instructions. Cell lines transfected for luciferase/GFP expression were grown under zeocin selection, and high luciferase-expressing cells were isolated as GFP high populations by fluorescence-activated cell sorting (FACS) on a BD FACSAria flow cytometer.
Luciferase-expressing MDA-MB-468 and MDA-MB-453 cells were transfected with constructs for expression of wild-type EPHA2 (EPHA2-WT) (a gift from T. Pawson), mutant EPHA2-Y772F, EPHA2-K646M, or pcDNA3 vector control (Invitrogen) and grown under selection by G418 (A1720). Resistant colonies were pooled to create polyclonal populations for each cell line. Stably transfected cells were stained with mouse anti-EPHA2-phycoerythrin (PE) conjugate (371805) (R&D Systems, FAB3035P) at 8 ml per 10 6 cells according to the manufacturer's instructions. Cells were counterstained with DAPI (0.2 mg/ml) to discern live cells before cell populations were isolated by FACS on the basis of their quantity of EPHA2 at the surface.
Targeted analysis of EPHA2 abundance by MS
Selected reaction monitoring (SRM) was used to analyze the expression of wild-type EPHA2 or mutant EPHA2-Y772F and EPHA2-K646M in cell lines. Total cell lysates were resolved by SDS-PAGE, and gel bands at 130-kD molecular weight were excised for in-gel digestion and targeted analysis by LC-MS as previously described (73) . Characteristic peptides and transitions monitored for EPHA2-K646M and EPHA2-Y772F are provided in table S8. Raw data files produced in Xcalibur were analyzed using Skyline v2.1 (MacCoss Lab of Biological Mass Spectrometry) (74) .
Relative peptide abundance was determined by summing the area under the curve from extracted ion chromatograms of at least three transitions. The abundance of EPHA2 was deduced from the total SRM signal intensity of three quantotypic peptides. For relative comparison of EPHA2 quantity in LM2 and parental MDA-MB-231 cell populations, LM2 and parental cells were SILAC-labeled with medium and heavy amino acids, respectively, to allow simultaneous SRM analysis of both populations. The total intensity of EPHA2 peptides was normalized to total protein quantities in each cell population.
For relative quantification of EPHA2 in the LM2 cells from SILACbased coculture experiments, lysates were incubated with an antibody recognizing human EPHA2 (Santa Cruz Biotechnology, sc-924; 1 mg of antibody per 500 mg of protein) under rotation at 4°C overnight. Protein A-conjugated Sepharose was washed and equilibrated in Triton X-100 lysis buffer before addition to complexes for a further rotation of 1 to 2 hours to immunoprecipitate EPHA2. Beads were collected by centrifugation and washed in Triton X-100 lysis buffer before isolated complexes were resolved by SDS-PAGE for in-gel digest, discovery LC-MS/MS analysis, and total protein relative quantification as described above. Normalization was carried out on the basis of the log 2 (H/M) ratio of the input samples before EPHA2 enrichment.
In vitro kinase activity assay HEK293T cells were transfected with pcDNA3 expression vectors for EPHA2-WT, EPHA2-Y772F, EPHA2-K646M, or empty vector control and grown for 48 hours before lysis in Triton X-100 lysis buffer. EPHA2 antibody (sc-924) was conjugated onto MagReSyn beads (ReSyn Biosciences, MR-PRA002) with overnight rotation at 4°C. Immunoprecipitation of EPHA2 was carried out using 0.5 mg of antibody per 500 mg of protein lysate. The kinase reaction was carried out as described previously (75) with minor modifications. Briefly, the bead-EPHA2 complexes were washed twice in the kinase reaction buffer [KRB; 20 mM Hepes (pH 7.5), 2.5 mM MgCl 2 , 4 mM MnCl 2 , 0.1 mM Na 3 VO 4 , and 100 mM adenosine triphosphate (ATP)] before incubation in 30 ml of KRB supplemented with 5 mg of human a-enolase (SRP6109) for 1 hour at room temperature. Supernatants were collected and transferred onto a plate for the kinase activity readout using an ADP-Glo kit (Promega, V9101) according to the manufacturer's instructions.
EPHA2 stimulation with clustered ephrinA1
Cancer cells at~70% confluency in six-well plates were serum-starved overnight before stimulation with artificially clustered ephrinA1. Clustered ligand was freshly prepared by mixing ephrinA1-Fc with antibody recognizing human IgG Fc (Jackson ImmunoResearch, 109-001-008-JIR) in a ratio of 1 mg:1.2 mg with rotation for a minimum of 1 hour at 4°C. Clustered ephrinA1 was diluted to 2 mg/ml in serum-free medium, and 700 ml was used to stimulate each well of cancer cells. After incubation with ephrinA1 at 37°C, 5% CO 2 for the specified times, cells were washed and lysed for Western blot analysis.
Western blotting
Cells were lysed on ice in Triton X-100 lysis buffer, and equal amounts of total protein were resolved by SDS-PAGE before transfer onto nitrocellulose membranes (LI-COR, 92631092) by a wet transfer system (Bio-Rad). Membranes were blocked in Roti-Block (Carl Roth, A151.2) for 30 min at room temperature before probing for target proteins. Primary antibodies used in this study were mouse b-actin (AC-15) (Abcam, ab6276; 1:5000), rabbit GAPDH (FL-335) ( . IRDye-conjugated anti-rabbit IgG, DyLight 800 (Cell Signaling Technology, #5151) and anti-mouse IgG, DyLight 680 (Cell Signaling Technology, #5470) were used as secondary antibodies at 1:15,000. Visualization of Western blots and densitometry analyses based on raw integrated intensity values were conducted using the Odyssey infrared imaging system and software (LI-COR Biosciences).
Statistical analysis
Unless otherwise indicated, data are expressed as means ± SEM calculated from a minimum of three independent experiments. A number of independent experiments are indicated on respective graphs (n) or represented as individual points. Statistical differences between two groups were assessed by two-sided, ratio paired, or unpaired t tests using GraphPad Prism software.
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